Biogen Idec MA, Inc. v. Japanese Foundation for Cancer Research

38 F. Supp. 3d 162, 2014 U.S. Dist. LEXIS 70316, 2014 WL 2167677
CourtDistrict Court, D. Massachusetts
DecidedMay 22, 2014
DocketCivil No. 13-13061-FDS
StatusPublished
Cited by2 cases

This text of 38 F. Supp. 3d 162 (Biogen Idec MA, Inc. v. Japanese Foundation for Cancer Research) is published on Counsel Stack Legal Research, covering District Court, D. Massachusetts primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Biogen Idec MA, Inc. v. Japanese Foundation for Cancer Research, 38 F. Supp. 3d 162, 2014 U.S. Dist. LEXIS 70316, 2014 WL 2167677 (D. Mass. 2014).

Opinion

MEMORANDUM AND ORDER ON MOTIONS TO DISMISS

SAYLOR, District Judge.

This claim arises out of a decision of the United States Patent and Trademark Office (“PTO”) Patent Trial and Appeal Board (“PTAB”). On July 16, 2013, the PTO declared an interference between various claims of U.S. Patent Application No. 08/253,843 (currently owned by Biogen Idee MA, Inc.) and U.S. Patent Application [163]*163No. 08/463,757 (currently owned by Japanese Foundation for Cancer Research and licensed to Bayer Pharma AG). On October 3, 2013, the PTAB found that the outcome of prior interference proceedings estopped the assertion of the claims of the '843 application and finally refused those claims. Dissatisfied with the PTAB’s decision, Biogen Idee sought review by this Court pursuant to 35 U.S.C. § 146 and 28 U.S.C. §§ 1331 and 1338(a).

Defendants have moved to dismiss the claim for lack of personal and subject-matter jurisdiction. For the reasons set forth below, this Court lacks subject-matter jurisdiction and will therefore transfer the action to the United States Court of Appeals for the Federal Circuit.

I. Background

The underlying dispute concerns human fibroblast interferon (“hFIF”), a human protein that possesses useful antiviral and immunological effects and is employed, among other things, to treat multiple sclerosis. The '843 and '757 applications both contain claims involving hFIF proteins.

In the United States, only one patent is permitted for any given patentable invention. For most of its history, the American patent system granted patents to the first person to invent the patentable invention. If multiple parties claiming the same invention disputed which first invented it, there were procedures to determine which one was entitled to the patent. Such procedures include interference proceedings before the Board of Patent Appeals and Interferences (“BPAI”).

In 2011, Congress passed the LeahySmith America Invents Act (“AIA”), Pub.L. No. 112-29, 125 Stat. 284 (2011), converting the patent system from “first-to-invent” to “first-inventor-to-file.” Under the new framework, if multiple parties claim the same invention, the first party to file a patent application generally is entitled to the patent. Of course, many patents issued under the old, first-to-invent framework remain in effect and may be subject to dispute. The issue here arises out of the transition from the old system to the new.

A. Prior Statutory Framework

Under the old system, the Director of the PTO was authorized to declare an interference between different patents or patent applications when they appeared to claim the same invention. 35 U.S.C. § 135 (2006). The BPAI would then conduct a proceeding to determine priority of'invention and patentability. Id. Once the BPAI rendered a final decision, an aggrieved party could either seek review in the Court of Appeals for the Federal Circuit, 35 U.S.C. § 141 (2006), or in a district court that had personal jurisdiction over the winning interferent, id. § 146.

B. Current Statutory Framework

On September 16, 2011, the AIA became law. It instituted a phased implementation of the Act’s provisions, with most changes going into effect on September 16, 2012, or March 16, 2013 (that is, twelve or eighteen months after enactment).

Interference proceedings have been abolished. Instead, under the new § 135, the Director of the PTO may institute a derivation proceeding to determine whether the first-filing inventor derived (essentially, misappropriated) the claimed invention from a later-filing inventor. 35 U.S.C. § 135(a), (b). Those proceedings are heard by the PTAB, which has replaced the BPAI. 35 U.S.C. § 6; see AIA § 3(j)(l). Applicants who are dissatisfied with the final decision of the PTAB in a derivation may seek review in the Federal Circuit, 35 U.S.C. § 141, or in the District [164]*164Court for the Eastern District of Virginia, id. § 146.

C. Procedural Background

On June 3, 1994, Walter C. Fiers filed the '843 patent application, which Biogen Idee now owns.1 The '843 application was a division of an earlier patent application by Fiers, no. 07/387,503, filed July 28, 1989, which was a division of patent application no. 06/250,609, filed April 3, 1981. On June 5, 1995, Haruo Sugano, Masami Muramatsu, and Tadatsugu Taniguehi filed the '757 patent application, which JFCR now owns. The '757 application claims priority to patent application no. 06/201,-359, which also was filed by Sugano.-

On August 30, 1983, the PTO declared an interference (no. 101,096) between the '609 and '359 applications concerning hFIF DNA. The BPAI awarded priority to the Sugano '359 application. That finding was upheld on appeal. Fiers v. Revel, 984 F.2d 1164 (Fed.Cir.1993).

On July 16, 2013, the PTO declared an interference (no. 105,939) between the '843 and '757 applications, which both contain claims to hFIF. At the same time, the PTO issued an Order to Show Cause to Fiers to show why judgment should not be entered against him based on interference estoppel and issue preclusion from the earlier '096 interference. Fiers responded to the Order, as did Sugano. Fiers also filed a paper presenting the issues of his intended motions in the interference proceeding, which included obviousness, written description, enablement, and priority.

On October 3, 2013, the PTAB found that because of the '096 interference, Fiers was estopped from asserting the claims in the '843 application. The PTAB entered judgment against Fiers and ordered that the claims in the '843 application be finally refused.

On December 2, 2013, Biogen Idee filed suit in this Court against JFCR and against the interested parties whom JFCR had listed in the interference: Bayer Pharma AG, Kyowa Hakko Kirin Co., Ltd., and Toray Industries, Inc. On March 28, 2014, JFCR and Bayer moved to dismiss the complaint for lack of personal and subject-matter jurisdiction under Fed.R.Civ.P. 12(b)(1), 12(b)(2), and 12(b)(6). On April 2, 2014, the Court dismissed without prejudice all claims against Kyowa and Toray pursuant to the parties’ agreement that they were not indispensable parties.

II. Standard of Review

Federal courts are courts of limited jurisdiction. They possess only those powers granted by either the Constitution or statute, and cannot adjudicate claims absent such power. See, e.g., Kokkonen v. Guardian Life Ins. Co. of Am.,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
38 F. Supp. 3d 162, 2014 U.S. Dist. LEXIS 70316, 2014 WL 2167677, Counsel Stack Legal Research, https://law.counselstack.com/opinion/biogen-idec-ma-inc-v-japanese-foundation-for-cancer-research-mad-2014.